Horizon Therapeutics PLC
NASDAQ:HZNP
Horizon Therapeutics PLC
Operating Income
Horizon Therapeutics PLC
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Horizon Therapeutics PLC
NASDAQ:HZNP
|
Operating Income
$567.6m
|
CAGR 3-Years
66%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Alkermes Plc
NASDAQ:ALKS
|
Operating Income
$420.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
28%
|
|
Amarin Corporation PLC
NASDAQ:AMRN
|
Operating Income
-$26m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
25%
|
CAGR 10-Years
16%
|
|
Prothena Corporation PLC
NASDAQ:PRTA
|
Operating Income
-$191m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-17%
|
|
M
|
Mural Oncology PLC
NASDAQ:MURA
|
Operating Income
-$196.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Horizon Therapeutics PLC's Operating Income?
Operating Income
567.6m
USD
Based on the financial report for Jun 30, 2023, Horizon Therapeutics PLC's Operating Income amounts to 567.6m USD.
What is Horizon Therapeutics PLC's Operating Income growth rate?
Operating Income CAGR 3Y
66%
Over the last year, the Operating Income growth was -37%. The average annual Operating Income growth rates for Horizon Therapeutics PLC have been 66% over the past three years .